[ET Net News Agency, 29 July 2025] Nomura raised the target price for Hengrui Pharma
(01276) to HKD80.57 from HKD71.5 and upgraded the rating to "buy" from "neutral".
The research house said Hengrui Pharma is likely to benefit from the prevailing positive
sentiment surrounding out-licensing of innovative drugs. (rc)